Prevention of Bone Loss by Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist up to One Year following Discontinuing Treatment

Lignende værker

• Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer
  af: Hershman, Dawn L., et al.
  Udgivet: (2008)
• High Prevalence of Vitamin D Deficiency Despite Supplementation in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy
  af: Crew, Katherine D., et al.
  Udgivet: (2009)
• Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis
  af: Cohen, Adi, et al.
  Udgivet: (2015)
• Adherence to and persistence with zoledronic acid treatment for osteoporosis—reasons for early discontinuation
  af: Spångeus, Anna, et al.
  Udgivet: (2020)
• Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy
  af: Yu, Bo, et al.
  Udgivet: (2010)